Frontiers in ophthalmology · 2025
Secukinumab in refractory non-infectious anterior uveitis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Olivas-Vergara Otto M, Hernanz Inés, Borges-Deniz Pablo E, Romero-Bueno Fredeswinda, Sanchez-Pernaute Olga, Carreño Ester
Аннотация
BACKGROUND: Secukinumab is a monoclonal antibody that selectively neutralizes interleukin-17A and has shown efficacy in the treatment of psoriatic arthritis, psoriasis, and axial spondyloarthritis. Its use in non-anterior non-infectious uveitis is controversial, with evidence generally not supporting its effectiveness in these conditions. However, the role of secukinumab in anterior non-infectious uveitis remains unclear.
METHODS: Case series. Five patients with biological therapy-refractory non-infectious anterior uveitis who were treated with secukinumab were included.
RESULTS: All 5 patients experienced a uveitis flare-up during treatment, and secukinumab failed to induce long-term remission in 2 of these patients, who also had uncontrolled systemic disease.
CONCLUSION: Secukinumab failed to prevent uveitis flare-up in these patients with biological therapy-refractory disease. Further studies are necessary to determine the potential role of secukinumab in the treatment of anterior uveitis.
METHODS: Case series. Five patients with biological therapy-refractory non-infectious anterior uveitis who were treated with secukinumab were included.
RESULTS: All 5 patients experienced a uveitis flare-up during treatment, and secukinumab failed to induce long-term remission in 2 of these patients, who also had uncontrolled systemic disease.
CONCLUSION: Secukinumab failed to prevent uveitis flare-up in these patients with biological therapy-refractory disease. Further studies are necessary to determine the potential role of secukinumab in the treatment of anterior uveitis.